|1.||Strand, V: 12 articles (09/2014 - 02/2000)|
|2.||Emery, Paul: 9 articles (10/2005 - 02/2002)|
|3.||Smolen, Josef S: 8 articles (01/2014 - 06/2004)|
|4.||Emery, P: 8 articles (11/2007 - 05/2000)|
|5.||Strand, Vibeke: 8 articles (04/2005 - 01/2002)|
|6.||Breedveld, F C: 7 articles (09/2004 - 06/2000)|
|7.||Fadillioglu, Ersin: 6 articles (04/2014 - 05/2006)|
|8.||Cutolo, Maurizio: 6 articles (01/2014 - 01/2009)|
|9.||Rozman, B: 6 articles (08/2009 - 01/2001)|
|10.||Kalden, Joachim R: 6 articles (08/2005 - 09/2002)|
10/01/2008 - "Leflunomide is an immunomodulating agent with proven efficacy in rheumatoid arthritis. "
11/01/2000 - "In phase II and III clinical trials of active rheumatoid arthritis, leflunomide was shown to improve primary and secondary outcome measures with a satisfactory safety profile. "
12/01/2002 - "It has been shown that leflunomide is effective in treating active rheumatoid arthritis(RA) in a placebo-controlled phase II study. "
06/01/2012 - "Leflunomide, a disease-modifying antirheumatic drug, has been shown to be effective in the management of rheumatoid arthritis (RA). "
04/01/2002 - "Leflunomide, a new oral immunomodulatory agent, is effective for the treatment of rheumatoid arthritis. "
|2.||Autoimmune Diseases (Autoimmune Disease)
01/01/1991 - "Thus, leflunomide, which is effective against autoimmune diseases and reactions leading to graft rejection, would seem to have a mode of action separating it from known immunosuppressive drugs."
01/01/2012 - "Leflunomide (LEF) is effective not only in different animal models of autoimmune diseases and the therapy of patients with rheumatoid arthritisbut also in graft rejection. "
02/01/2010 - "In the present research, we studied the effect of leflunomide, a novel immunosuppressive and antiinflammatory agent against autoimmune disease, on hepatic regeneration after PH in Wistar Albino rats. "
11/01/2008 - "Leflunomide is used in the treatment of autoimmune diseases as an anti-inflammatory agent. "
11/01/2004 - "Leflunomide is a novel immunosuppressive and anti-inflammatory agent for the treatment of autoimmune disease. "
08/27/2010 - "Leflunomide was initiated after a median of three episodes of CMV viremia, with a mean peak viral load of 245,826 copies/mL. Initial clearance of CMV viremia was observed in 14 of 17 patients (82%), and 9 of 17 (53%) patients achieved a long-term suppression of CMV recurrences. "
06/01/2012 - "Randomized studies are needed to determine the utility of leflunomide for BK viremia and nephropathy."
06/01/2012 - "Leflunomide has been studied for the treatment of BK viremia and nephropathy, but there are limited data on the utility of leflunomide therapeutic drug monitoring. "
08/27/2010 - "Leflunomide, alone or in combination, has potential utility in treatment of complex CMV syndromes and in long-term suppression of viremia. "
08/27/2010 - "Higher peak viral load and higher viral load at the start of leflunomide therapy were associated with failure to suppress viremia. "
01/01/2005 - "In this open study of patients with active AS only those with peripheral arthritis improved significantly with leflunomide treatment. "
02/01/2010 - "Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008)."
01/01/2016 - "This study included individuals enrolled in the Early Arthritis inception cohort at the Royal Adelaide Hospital between 2000 and 2013 who received leflunomide. "
01/01/2014 - "To evaluated the effect and mechanism of leflunomide (LEF) in murine model of collage-induced arthritis (CIA) on modulating the balance of Th17/Treg cells. "
01/01/2014 - "Modulating effects of leflunomide on the balance of Th17/Treg cells in collageninduced arthritis DBA/1 mice."
|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
06/01/2004 - "Significant differences in favor of leflunomide were also observed in the proportions of patients achieving modified American College of Rheumatology 20% improvement criteria, improvement in the designated psoriasis target lesion, and mean changes from baseline in Psoriasis Area and Severity Index scores and quality-of-life assessments. "
12/01/2008 - "Is leflunomide effective in the treatment of psoriasis in a patient who is unable to benefit from standard first- and second-line therapies and needs an affordable treatment option?"
06/01/2004 - "Leflunomide is an effective treatment for PsA and psoriasis, providing a safe and convenient alternative to current therapies."
05/01/2004 - "Our data suggest that leflunomide for plaque-type psoriasis is a safe and clinically effective option as monotherapy. "
01/01/2006 - "Leflunomide has shown promise in the treatment of psoriasis. "
|5.||Intravenous Immunoglobulins (IVIG)
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Cholestyramine Resin (Questran)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)
|4.||Homologous Transplantation (Allograft)